Shortage Watch Free FDA drug-shortage watch

← all medications

Rivaroxaban For Suspension

Brand names: Xarelto

Category: Hematology

Not specified 1

FDA status: To Be Discontinued · Last FDA update: Sep 18, 2026 · First posted: Sep 18, 2026 · 1 manufacturers, 1 listed presentations

As of Sep 18, 2026, the FDA lists Rivaroxaban For Suspension as being discontinued. Of 1 manufacturer presentations, 1 Not specified.

Ask your pharmacist: which of the 1 manufacturers below can they order right now, and whether a different strength or form of Rivaroxaban For Suspension is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
Presentation & package NDCManufacturerAvailabilityFDA note
Xarelto, For Suspension, 155 mg (NDC 50458-575-01)
NDC 50458-575-01		 Janssen Pharmaceuticals Not specified Business Decision

Related medications in shortage

Other Hematology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Rivaroxaban For Suspension (FDA data as of Sep 18, 2026). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Rivaroxaban For Suspension. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Rivaroxaban For Suspension.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/rivaroxaban-for-suspension.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).